Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Consensus: "Moderate Buy" — 17 analysts cover Nuvalent (16 buys, 1 sell) with an average 1‑year price target of $137.25; recent targets range from about $116 to $155.
• Insider selling accelerated recently: insiders sold 50,023 shares worth roughly $5.18 million in the last quarter, though corporate insiders still own about 10.20% of the stock.
• Company and stock snapshot: NUVL opened at $101.47, has a market cap of ~$7.98 billion and a negative PE (-17.35), a 1‑year range of $63.56–$113.01, and is a clinical‑stage oncology firm advancing lead candidates NVL‑520 (RET) and NVL‑655 (KRAS G12D).

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) has received an average recommendation of "Moderate Buy" from the seventeen ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and sixteen have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $137.25.

A number of research firms recently commented on NUVL. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvalent in a report on Tuesday, April 21st. HC Wainwright restated a "buy" rating and issued a $155.00 price objective on shares of Nuvalent in a research report on Tuesday, April 21st. Wedbush reaffirmed an "outperform" rating and set a $125.00 price objective on shares of Nuvalent in a research note on Wednesday, April 8th. Cantor Fitzgerald increased their target price on shares of Nuvalent from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Friday, February 27th. Finally, Wells Fargo & Company began coverage on Nuvalent in a research note on Monday, March 30th. They issued an "overweight" rating and a $116.00 target price on the stock.

Nuvalent Price Performance

Shares of NUVL stock opened at $101.47 on Wednesday. The business has a 50-day moving average of $101.96 and a 200 day moving average of $102.18. Nuvalent has a 1-year low of $63.56 and a 1-year high of $113.01. The stock has a market capitalization of $7.98 billion, a PE ratio of -17.35 and a beta of 1.15.

Insiders Place Their Bets

In other news, insider Deborah Ann Miller sold 5,500 shares of Nuvalent stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $99.22, for a total value of $545,710.00. Following the sale, the insider directly owned 59,634 shares in the company, valued at approximately $5,916,885.48. This trade represents a 8.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Henry E. Pelish sold 3,093 shares of the firm's stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $104.48, for a total value of $323,156.64. Following the completion of the sale, the insider directly owned 65,604 shares of the company's stock, valued at $6,854,305.92. The trade was a 4.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 50,023 shares of company stock worth $5,184,517. Corporate insiders own 10.20% of the company's stock.

Hedge Funds Weigh In On Nuvalent

Several hedge funds and other institutional investors have recently modified their holdings of NUVL. GAMMA Investing LLC lifted its stake in shares of Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company's stock valued at $34,000 after purchasing an additional 108 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in Nuvalent during the 3rd quarter valued at about $38,000. Eastern Bank bought a new position in shares of Nuvalent during the third quarter valued at approximately $52,000. NBC Securities Inc. purchased a new position in shares of Nuvalent during the fourth quarter valued at approximately $125,000. Finally, KBC Group NV boosted its position in shares of Nuvalent by 24.1% in the 4th quarter. KBC Group NV now owns 1,527 shares of the company's stock worth $154,000 after purchasing an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company's stock.

Nuvalent Company Profile

Nuvalent, Inc NASDAQ: NUVL is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.